High expression of Ras-specific guanine nucleotide-releasing factor 2 (RasGRF2) in lung adenocarcinoma is associated with tumor invasion and poor prognosis.

Autor: Nakagawa T; Department of Pathology, University of Tsukuba Hospital, Ibaraki, Japan.; Doctoral Program in Biomedical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan., Kim Y; Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Kano J; Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Murata Y; Department of Pathology, University of Tsukuba Hospital, Ibaraki, Japan., Kosibaty Z; Tsukuba Human Tissue Diagnostic Center, University of Tsukuba Hospital, Ibaraki, Japan., Noguchi M; Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Sakamoto N; Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Jazyk: angličtina
Zdroj: Pathology international [Pathol Int] 2021 Apr; Vol. 71 (4), pp. 255-260. Date of Electronic Publication: 2021 Mar 11.
DOI: 10.1111/pin.13069
Abstrakt: The expression of Ras-specific guanine nucleotide-releasing factor 2 (RasGRF2) in lung adenocarcinomas was examined using immunohistochemistry in relation to clinicopathological characteristics and prognosis. In comparison to low expression, high expression of RasGRF2 was more closely associated with poor prognosis. Interestingly, expression of phosphorylated epithelial cell transforming 2 (pECT2), which - like RasGRF2 - is also a guanine-nucleotide exchange factor, was also associated with prognosis, and patients with high expression of both RasGRF2 and pECT2 had a much poorer outcome than those who were negative for both.
(© 2021 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje